248 related articles for article (PubMed ID: 24767679)
1. A 3'UTR polymorphism modulates mRNA stability of the oncogene and drug target Polo-like Kinase 1.
Akdeli N; Riemann K; Westphal J; Hess J; Siffert W; Bachmann HS
Mol Cancer; 2014 Apr; 13():87. PubMed ID: 24767679
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-100 is a potential molecular marker of non-small cell lung cancer and functions as a tumor suppressor by targeting polo-like kinase 1.
Liu J; Lu KH; Liu ZL; Sun M; De W; Wang ZX
BMC Cancer; 2012 Nov; 12():519. PubMed ID: 23151088
[TBL] [Abstract][Full Text] [Related]
3. Regulation of PLK1 through competition between hnRNPK, miR-149-3p and miR-193b-5p.
Shin CH; Lee H; Kim HR; Choi KH; Joung JG; Kim HH
Cell Death Differ; 2017 Nov; 24(11):1861-1871. PubMed ID: 28708135
[TBL] [Abstract][Full Text] [Related]
4. Nitric oxide down-regulates polo-like kinase 1 through a proximal promoter cell cycle gene homology region.
Zhang J; Wang S; Kern S; Cui X; Danner RL
J Biol Chem; 2007 Jan; 282(2):1003-9. PubMed ID: 17121839
[TBL] [Abstract][Full Text] [Related]
5. Polo-like kinase 1 regulates cell proliferation and is targeted by miR-593* in esophageal cancer.
Ito T; Sato F; Kan T; Cheng Y; David S; Agarwal R; Paun BC; Jin Z; Olaru AV; Hamilton JP; Selaru FM; Yang J; Matsumura N; Shimizu K; Abraham JM; Shimada Y; Mori Y; Meltzer SJ
Int J Cancer; 2011 Nov; 129(9):2134-46. PubMed ID: 21170987
[TBL] [Abstract][Full Text] [Related]
6. RNAi prodrugs decrease elevated mRNA levels of Polo-like kinase 1 in ex vivo cultured primary cells from pediatric acute myeloid leukemia patients.
Kolosenko I; Goroshchuk O; Vidarsdottir L; Björklund AC; Dowdy SF; Palm-Apergi C
FASEB J; 2021 May; 35(5):e21476. PubMed ID: 33788972
[TBL] [Abstract][Full Text] [Related]
7. Polo-like kinase 1 inhibits the activity of positive transcription elongation factor of RNA Pol II b (P-TEFb).
Jiang L; Huang Y; Deng M; Liu T; Lai W; Ye X
PLoS One; 2013; 8(8):e72289. PubMed ID: 23977272
[TBL] [Abstract][Full Text] [Related]
8. Reciprocal activation between PLK1 and Stat3 contributes to survival and proliferation of esophageal cancer cells.
Zhang Y; Du XL; Wang CJ; Lin DC; Ruan X; Feng YB; Huo YQ; Peng H; Cui JL; Zhang TT; Wang YQ; Zhang H; Zhan QM; Wang MR
Gastroenterology; 2012 Mar; 142(3):521-530.e3. PubMed ID: 22108192
[TBL] [Abstract][Full Text] [Related]
9. Kinome inhibition reveals a role for polo-like kinase 1 in targeting post-transcriptional control in cancer.
Al-Qahtani QH; Moghrabi WN; Al-Yahya S; Al-Haj L; Al-Saif M; Mahmoud L; Al-Mohanna F; Al-Souhibani N; Alaiya A; Hitti E; Khabar KSA
Mol Oncol; 2021 Aug; 15(8):2120-2139. PubMed ID: 33411958
[TBL] [Abstract][Full Text] [Related]
10. Selective blockade of cancer cell proliferation and anchorage-independent growth by Plk1 activity-dependent suicidal inhibition of its polo-box domain.
Park JE; Kim TS; Kim BY; Lee KS
Cell Cycle; 2015; 14(22):3624-34. PubMed ID: 26513691
[TBL] [Abstract][Full Text] [Related]
11. p53-dependent repression of polo-like kinase-1 (PLK1).
McKenzie L; King S; Marcar L; Nicol S; Dias SS; Schumm K; Robertson P; Bourdon JC; Perkins N; Fuller-Pace F; Meek DW
Cell Cycle; 2010 Oct; 9(20):4200-12. PubMed ID: 20962589
[TBL] [Abstract][Full Text] [Related]
12. Suppression of Polo like kinase 1 (PLK1) by p21(Waf1) mediates the p53-dependent prevention of caspase-independent mitotic death.
Lin YC; Sun SH; Wang FF
Cell Signal; 2011 Nov; 23(11):1816-23. PubMed ID: 21726628
[TBL] [Abstract][Full Text] [Related]
13. MiR-296-5p suppresses papillary thyroid carcinoma cell growth via targeting PLK1.
Zhou SL; Tang QL; Zhou SX; Ren RZ
Eur Rev Med Pharmacol Sci; 2019 Mar; 23(5):2084-2091. PubMed ID: 30915753
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological significance of Polo-like kinase 1 (PLK1) expression in human malignant glioma.
Cheng MW; Wang BC; Weng ZQ; Zhu XW
Acta Histochem; 2012 Sep; 114(5):503-9. PubMed ID: 22000864
[TBL] [Abstract][Full Text] [Related]
15. Structure of the catalytic domain of human polo-like kinase 1.
Kothe M; Kohls D; Low S; Coli R; Cheng AC; Jacques SL; Johnson TL; Lewis C; Loh C; Nonomiya J; Sheils AL; Verdries KA; Wynn TA; Kuhn C; Ding YH
Biochemistry; 2007 May; 46(20):5960-71. PubMed ID: 17461553
[TBL] [Abstract][Full Text] [Related]
16. Plk1-targeted small molecule inhibitors: molecular basis for their potency and specificity.
Murugan RN; Park JE; Kim EH; Shin SY; Cheong C; Lee KS; Bang JK
Mol Cells; 2011 Sep; 32(3):209-20. PubMed ID: 21809214
[TBL] [Abstract][Full Text] [Related]
17. Targeting polo-like kinase 1 by NMS-P937 in osteosarcoma cell lines inhibits tumor cell growth and partially overcomes drug resistance.
Sero V; Tavanti E; Vella S; Hattinger CM; Fanelli M; Michelacci F; Versteeg R; Valsasina B; Gudeman B; Picci P; Serra M
Invest New Drugs; 2014 Dec; 32(6):1167-80. PubMed ID: 25193492
[TBL] [Abstract][Full Text] [Related]
18. Design and synthesis of a cell-permeable, drug-like small molecule inhibitor targeting the polo-box domain of polo-like kinase 1.
Srinivasrao G; Park JE; Kim S; Ahn M; Cheong C; Nam KY; Gunasekaran P; Hwang E; Kim NH; Shin SY; Lee KS; Ryu E; Bang JK
PLoS One; 2014; 9(9):e107432. PubMed ID: 25211362
[TBL] [Abstract][Full Text] [Related]
19. p53 is not directly relevant to the response of Polo-like kinase 1 inhibitors.
Sanhaji M; Kreis NN; Zimmer B; Berg T; Louwen F; Yuan J
Cell Cycle; 2012 Feb; 11(3):543-53. PubMed ID: 22262171
[TBL] [Abstract][Full Text] [Related]
20. The Functional Significance of Posttranslational Modifications on Polo-Like Kinase 1 Revealed by Chemical Genetic Complementation.
Lasek AL; McPherson BM; Trueman NG; Burkard ME
PLoS One; 2016; 11(2):e0150225. PubMed ID: 26919439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
